- CH₣892.19m
- CH₣721.85m
- €104.17m
Brief: Redhill Biopharma Further Expands Opaganib Manufacturing Capacity For Covid-19 With Cosmo Pharmaceuticals
Brief: Cosmo Announces Successful Outcome Of Rifamycin 600Mg Phase II Trial In IBS-D
Brief: Cosmo Pharmaceuticals Announces Amendment Of Its Investment Agreement With Acacia
Swiss stocks - Factors to watch on December 4
Brief: Cosmo Pharmaceuticals Appoints New Chief Medical Officer
Brief: Cosmo Pharmaceuticals Expands Agreement With Dr. Falk Pharma For Rifamycin SV MMX
Brief: Cosmo Pharmaceuticals Announces Approval Of Eleview(R) In Japan
Cassiopea: Rallies on FDA approval for acne treatment
Cassiopea gets U.S. FDA approval for acne treatment Winlevi (updated)
Brief: Cosmo Pharmaceuticals Says European Commission Approves Methylthioninium Chloride Cosmo
Brief: Cosmo And Redhill Biopharma To Expand Strategic Partnership
Brief: Cosmo Pharmaceuticals H1 Operating Profit Up At EUR 2.7 Mln
Brief: PAION U.S. License Agreement For BYFAVOTM Between Paion And Cosmo
Brief: Cosmo Pharmaceuticals' Rifamycin SV MMX Gets Marketing Authorization In Italy
Swiss stocks - Factors to watch on July 3
Brief: Cosmo Pharmaceuticals Announces U.S. FDA Approval Of Byfavo(Tm)
Cosmo Pharma: Shares jump on EU recommendation of colonoscopy drug
Brief: Cosmo Gets Positive EMA CHMP Opinion On Methylene Blue MMX
Live Markets: On the radar: Fresh PMIs, UK lockdown easing and Sanofi's vaccine